Nautilus Biotechnology vs Microbiotica

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (37 vs 39)
Nautilus Biotechnology logo

Nautilus Biotechnology

EmergingBiotechnology

Single-Molecule Proteomics

Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previously impossible.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
32
Perplexity
42
Gemini
35

About

Nautilus Biotechnology is a proteomics company founded in 2016 and publicly listed on Nasdaq, developing a revolutionary platform for analyzing proteins at single-molecule resolution. While genomics has transformed medicine through DNA and RNA sequencing, the proteome is the actual functional layer of biology where drug targets, disease biomarkers, and therapeutic mechanisms operate. Nautilus is building a platform that can identify and quantify thousands of proteins simultaneously from tiny biological samples using a fluorescence-based single-molecule detection approach without requiring mass spectrometry. The platform promises to enable proteomics studies at a scale and depth comparable to what next-generation sequencing delivered to genomics, unlocking new insights into disease biology and drug development. Nautilus is in the instrument development phase and targets pharmaceutical research, clinical diagnostics, and academic biology. The company has raised over $250M and is building manufacturing capabilities for a planned commercial instrument launch that could define a new era in proteomics research.

Full profile
Microbiotica logo

Microbiotica

EmergingBioTech

Microbiome Therapeutics

Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.

AI VisibilityBeta
Overall Score
D39
Category Rank
#1 of 2
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
47
Perplexity
43
Gemini
47

About

Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.

Full profile

AI Visibility Head-to-Head

37
Overall Score
39
#1
Category Rank
#1
64
AI Consensus
75
up
Trend
up
32
ChatGPT
47
42
Perplexity
43
35
Gemini
47
31
Claude
42
44
Grok
37

Key Details

Category
Single-Molecule Proteomics
Microbiome Therapeutics
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Nautilus Biotechnology
Single-Molecule Proteomics
Only Microbiotica
Microbiome Therapeutics

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.